MADRIGAL PHARMACEUTICALS, INC.


Associated tags: Liver disease, Therapy, Liver, NASH, THR, Medication, Fatty liver disease, Patient, Pharmaceutical industry, Madrigal

Locations: RARE, AST, BONE, WEST CONSHOHOCKEN, PA, US

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

Retrieved on: 
Wednesday, March 9, 2022
NASDAQ, Nasdaq, Therapy, NASH, Conference, Investor, Fatty liver disease, THR, GLOBE, Patient, Liver, Liver disease, Pharmaceutical industry, Madrigal

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.

Key Points: 
  • CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.
  • The fireside chat presentation will be webcast live and an archived recording will be available for replay in the Investors & Media section of the Madrigal website after the event.
  • Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need.
  • Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH.

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Thursday, February 24, 2022
Prucalopride, Head, Elastography, Regulatory affairs, Company, Senior, Liver, Nasdaq, NAFLD, NASH, Knowledge, Private Securities Litigation Reform Act, Research, Judgement, U.S. Securities and Exchange Commission, Therapy, Gastroenterology, Cirrhosis, Risk, Memorial Sloan Kettering Cancer Center, SEC, Safety, Bristol Myers Squibb, MAST, Accelerated approval (FDA), Disclosure, Program, Doctor of Philosophy, IQVIA, NASDAQ, THR, MRE, Forward-looking statement, Patient, Eli Lilly and Company, Communication, Takeda, GLOBE, Fatty liver disease, Income, Achievement, Research and development, Fibrosis, Annual report, University, Clinical trial, Liver disease, FDA, ELF, Guidances for statistics in regulatory affairs, Time, Pharmaceutical industry, Medical imaging, Cryptocurrency, Madrigal

CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.

Key Points: 
  • CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.
  • The frequency of serious adverse events was similar across placebo and active treatment arms and discontinuation for adverse events was low.
  • Dr. Labriola has 35 years of experience in clinical development overseeing the global registration of 20 medicines.
  • Undue reliance should not be placed on forward- looking statements, which speak only as of the date they are made.

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Retrieved on: 
Monday, January 31, 2022
NASH, Patient safety, Fatty liver disease, Safety, APOB, Patient, Cirrhosis, Biomarker, Fibrosis, NAS, OL, Magnetic resonance imaging, SE, Madrigal, Medical imaging, CFB

CONSHOHOCKEN, Pa., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced positive topline clinical data from the placebo-controlled, double-blind portion of its Phase 3 MAESTRO-NAFLD-1 (non-alcoholic fatty liver disease) safety study of resmetirom. The 52-week study demonstrated that resmetirom was safe and well-tolerated at 80 and 100 mg once a day dosing. Additionally, resmetirom helped patients with presumed non-alcoholic steatohepatitis (NASH) achieve significant, clinically relevant reductions in liver fat and atherogenic lipids.

Key Points: 
  • The lack of selectivity of older thyromimetic compounds, chemically-related toxicities and undesirable distribution in the body led to safety concerns.
  • Madrigal is currently conducting two Phase 3 Clinical trials, MAESTRO-NASH and MAESTRO-NAFLD-1, to demonstrate the safety and efficacy of resmetirom for the treatment of NASH.
  • MAESTRO-NASH is a Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with liver biopsy confirmed NASH and was initiated in March 2019.
  • Undue reliance should not be placed on forward- looking statements, which speak only as of the date they are made.

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

Retrieved on: 
Sunday, January 30, 2022
Liver, Liver disease, Fatty liver disease, Patient, Therapy, THR, Nasdaq, Online shopping, Pharmaceutical industry, Madrigal

To access the live webcast of the call please visit the Events and Presentations section of Madrigals website or click here .

Key Points: 
  • To access the live webcast of the call please visit the Events and Presentations section of Madrigals website or click here .
  • An archived webcast will be available on the Madrigal website after the event.
  • Madrigals lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)- selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.
  • For more information, visit www.madrigalpharma.com .

Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

Retrieved on: 
Monday, January 10, 2022
Clinical trial, Liver disease, Knowledge, Memorial Sloan Kettering Cancer Center, SEC, NAFLD, Safety, ELF, Disclosure, Risk, Head, Biostatistics, Liver, Fibrosis, CMO, Patient, Bristol Myers Squibb, NASDAQ, MRE, Health, Forward-looking statement, U.S. Securities and Exchange Commission, Annual report, MAST, Program, Time, Research, Senior, CEO, Private Securities Litigation Reform Act, Nasdaq, Communication, Fatty liver disease, THR, University, Judgement, Elastography, Cirrhosis, FDA, Therapy, Achievement, Accelerated approval (FDA), GLOBE, Non-alcoholic fatty liver disease, Pharmaceutical industry, Madrigal

CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer.

Key Points: 
  • CONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer.
  • We are pleased to welcome Dr. Labriola to Madrigal at this pivotal time for the company, said Becky Taub, M.D., President R&D and CMO of Madrigal.
  • NASH is one of the major remaining unmet needs in medicine today, and data Madrigal will be generating in 2022 from the MAESTRO clinical trials have the potential to shape NASH patient care, said Dr. Labriola.
  • I am looking forward to contributing to the companys industry-leading NASH clinical development program as we work to deliver a transformational therapy for patients.

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Retrieved on: 
Thursday, December 30, 2021
Safety, Non-alcoholic fatty liver disease, Private Securities Litigation Reform Act, Disclosure, Biomarker, U.S. Securities and Exchange Commission, Communication, ELF, FDA, Biopsy, Elastography, Clinical trial, GLOBE, MAST, Forward-looking statement, TG, Accelerated approval (FDA), NASDAQ, Magnetic resonance imaging, Liver disease, SEC, Knowledge, Fatty liver disease, Annual report, Patient, Research, Achievement, Therapy, MRE, Nasdaq, THR, Cirrhosis, Fibrosis, Liver, Judgement, Time, NAFLD, Risk, Pharmaceutical industry, Medical imaging, NAS, Madrigal

We now expect to announce topline 52-week results from the study in January 2022.

Key Points: 
  • We now expect to announce topline 52-week results from the study in January 2022.
  • Madrigal is currently conducting two Phase 3 Clinical trials, MAESTRO-NASH and MAESTRO-NAFLD-1, to demonstrate the safety and efficacy of resmetirom for the treatment of NASH.
  • MAESTRO-NASH is a Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with liver biopsy confirmed NASH and was initiated in March 2019.
  • Patients in MAESTRO-NAFLD-1 are randomized 1:1:1 to receive resmetirom 80 mg once a day, 100 mg once a day, or placebo.

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

Retrieved on: 
Tuesday, November 23, 2021
Patient, Fatty liver disease, Nasdaq, GLOBE, Liver disease, NASDAQ, Therapy, THR, Event, Liver, Pharmaceutical industry, Animal

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:

Key Points: 
  • CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:
    Fireside chat at 9:40 AM EST on Tuesday, November 30, 2021
    Fireside chat at 11:30 AM EST on Thursday, December 2, 2021
    The presentations will be webcast live and archived recordings will be available for replay in the Events & Presentations section of the Madrigal website for 90 days following the live presentations.
  • Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of fatty liver and cardio-metabolic diseases with high unmet medical need.
  • Madrigals lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)- selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO- NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.
  • For more information, visit www.madrigalpharma.com .

Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021

Retrieved on: 
Friday, November 12, 2021
MAST, Clinical trial, MRE, Metabolic syndrome, Non-alcoholic fatty liver disease, Doctor's visit, Principal, Pain, ELF, Disclosure, Therapy, Accelerated approval (FDA), Webcast, Communication, University of Oxford, Safety, Biomarker, Blood pressure, NAFLD, Research, Forward-looking statement, Hexanol, Liver, Liver disease, GLOBE, Cirrhosis, CAP, Time, Patient, FDA, Achievement, Private Securities Litigation Reform Act, Fatty liver disease, U.S. Securities and Exchange Commission, Hepatomegaly, NASDAQ, Knowledge, Inflammation, Risk, Non-cirrhotic portal fibrosis, AST, SEC, SGLT2, Elastography, Steatosis, Triglyceride, Annual report, PHASE 2, Judgement, Fibrosis, THR, Nasdaq, Pharmaceutical industry, Medical imaging

These new data from MAESTRO-NAFLD-1, our ongoing Phase 3 non-invasive study of resmetirom in patients with presumed NASH, reinforce and deepen our understanding of the therapeutic potential of resmetirom.

Key Points: 
  • These new data from MAESTRO-NAFLD-1, our ongoing Phase 3 non-invasive study of resmetirom in patients with presumed NASH, reinforce and deepen our understanding of the therapeutic potential of resmetirom.
  • Late-Breaking Poster Presentation (abstract #LP19): Friday, November 12th
    Biomarkers, imaging and safety in resmetirom 52-week non-cirrhotic NASH Phase 3 clinical trial, completed open-label arm of MAESTRO-NAFLD-1.
  • NASH cirrhotics with elevated baseline liver fat >=8% had 30% reduction in liver fat fraction and 18% reduction in liver volume.
  • Undue reliance should not be placed on forward- looking statements, which speak only as of the date they are made.

Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results

Retrieved on: 
Thursday, November 4, 2021

CONSHOHOCKEN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial results.

Key Points: 
  • CONSHOHOCKEN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial results.
  • Several abstracts summarizing data from the open-label arms of the MAESTRO-NAFLD-1 study have been accepted for presentation at AASLDs The Liver Meeting 2021.
  • Kia Motesharei, PhD, has joined Madrigal as Senior Vice President Business & Corporate Development.
  • As of September 30, 2021, Madrigal had cash, cash equivalents and marketable securities of $299.1 million, compared to $284.1 million at December 31, 2020.

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Monday, October 4, 2021
ELF, Mortality, Health, Elastography, Icahn School of Medicine at Mount Sinai, Private Securities Litigation Reform Act, Non-alcoholic fatty liver disease, Communication, Entrepreneurship, Judgement, Cirrhosis, Safety, Industry, SEC, Institute of Liver and Biliary Sciences, Liver, U.S. Securities and Exchange Commission, Mount Sinai, Association, NAFLD, CEO, Knowledge, Awareness, Disease, Incidence, Fatty liver disease, Liver disease, Clinical trial, Partnership, American Association of Clinical Endocrinologists, Achievement, Risk, Annual report, Therapy, NASDAQ, FDA, Cancer, Investor, Accelerated approval (FDA), FLF, Forward-looking statement, Fibrosis, Time, Education, GLOBE, THR, MRE, American Association, Diagnosis, Patient, Fund, Ownership, Research, Nasdaq, Dietary supplement, Pharmaceutical industry, Medical imaging

Today, Madrigal and the Fatty Liver Foundation will ring the Nasdaq closing bell to raise awareness of the need for more evidence-based screening and testing to improve diagnosis and staging of NAFLD/NASH.

Key Points: 
  • Today, Madrigal and the Fatty Liver Foundation will ring the Nasdaq closing bell to raise awareness of the need for more evidence-based screening and testing to improve diagnosis and staging of NAFLD/NASH.
  • NASH is known as a silent disease because many people dont know they have it until it has progressed to a dangerous stage.
  • Madrigal is providing an unrestricted grant to support FLFs NAFLD Screening Fund whose primary objective is to scale-up evidence-based screening and testing for NAFLD in a community setting.
  • These efforts would support, and potentially boost, the non-invasive screening needed to identify asymptomatic disease and diagnosing NAFLD/NASH patients at various points of progression.